Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells (Q39725130)

From Wikidata

Jump to navigation Jump to search

scientific article published on 22 March 2010

Language	Label	Description	Also known as
English	Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells	scientific article published on 22 March 2010

Statements

scholarly article

1 reference

Europe PubMed Central

14 September 2017

Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells (English)

1 reference

Europe PubMed Central

14 September 2017

phosphorylation

1 reference

based on heuristic

inferred from title

9

1 reference

Europe PubMed Central

14 September 2017

author name string

M P Albero

1

1 reference

Europe PubMed Central

14 September 2017

J M Vaquer

2

1 reference

Europe PubMed Central

14 September 2017

E J Andreu

3

1 reference

Europe PubMed Central

14 September 2017

J J Villanueva

4

1 reference

Europe PubMed Central

14 September 2017

L Franch

5

1 reference

Europe PubMed Central

14 September 2017

C Ivorra

6

1 reference

Europe PubMed Central

14 September 2017

E Poch

7

1 reference

Europe PubMed Central

14 September 2017

X Agirre

8

1 reference

Europe PubMed Central

14 September 2017

I Pérez-Roger

10

1 reference

Europe PubMed Central

14 September 2017

language of work or name

0 references

publication date

22 March 2010

1 reference

Europe PubMed Central

14 September 2017

1 reference

Europe PubMed Central

14 September 2017

29

1 reference

Europe PubMed Central

14 September 2017

22

1 reference

Europe PubMed Central

14 September 2017

3276-3286

1 reference

Europe PubMed Central

14 September 2017

https://scigraph.springernature.com/pub.10.1038/onc.2010.81

0 references

Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

21 January 2018

Establishment and characterization of A novel Philadelphia-chromosome positive chronic myeloid leukemia cell line, TCC-S, expressing P210 and P190 BCR/ABL transcripts but missing normal ABL gene

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

21 January 2018

Proteasome inhibition in cancer: development of PS-341.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

A cell cycle regulatory network controlling NF-kappaB subunit activity and function

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Targeting the UPS as therapy in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Proteasome proteolytic profile is linked to Bcr-Abl expression

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Translation of the Philadelphia chromosome into therapy for CML.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

PS-341 (Bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

The generation of nfkb2 p52: mechanism and efficiency

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Proteasome inhibitor drugs on the rise

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

RB, the conductor that orchestrates life, death and differentiation

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Skp2-dependent degradation of p27kip1 is essential for cell cycle progression

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Recycling the Cell Cycle

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1).

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

RhoE interferes with Rb inactivation and regulates the proliferation and survival of the U87 human glioblastoma cell line.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Two pathways to NF-kappaB.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Therapy options in imatinib failures

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

The role of myc in transformation by BCR-ABL.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Living with or without cyclins and cyclin-dependent kinases

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Proteasome inhibition as novel treatment strategy in leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Bortezomib: putting mantle cell lymphoma on death row.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: a gene expression profiling study with implications for potential combination therapies

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.81

31 March 2020

Identifiers

10.1038/ONC.2010.81

1 reference

Europe PubMed Central

14 September 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

14 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39725130&oldid=2089157835"